keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/28629689/advanced-power-doppler-technique-increases-synovial-vascularity-detection-in-patients-with-rheumatoid-arthritis
#1
Davide Orlandi, Salvatore Gitto, Silvia Perugin Bernardi, Angelo Corazza, Luca De Flaviis, Enzo Silvestri, Marco Amedeo Cimmino, Luca Maria Sconfienza
We compared the diagnostic performance of an advanced power Doppler technique (superb microvascular imaging [SMI]) with that of power Doppler Imaging (PDI) and B-mode ultrasound (US) in patients with early rheumatoid arthritis (RA) and RA under treatment with rituximab. Thirty patients (21 women aged 45 ± 11 y) affected by RA with remission to moderate disease activity were examined. Both hand joints were evaluated using US, PDI and SMI. Two radiologists reviewed all video clips and evaluated synovial vascularity intensity using a semi-quantitative scoring system...
June 16, 2017: Ultrasound in Medicine & Biology
https://www.readbyqxmd.com/read/28628469/six-joint-ultrasound-in-rheumatoid-arthritis-a-feasible-approach-for-implementing-ultrasound-in-remission
#2
Sibel Zehra Aydin, Esen Kasapoglu Gunal, Merve Ozata, Havva Keskin, Ayse Bilge Ozturk, Paul Emery, Maria Antonietta D'Agostino
OBJECTIVES: Subclinical disease activity in rheumatoid arthritis (RA) detected by imaging methods is predictive for flares and damage. Lack of time is the major limitation for not screening for subclinical disease in routine practice. We aimed to determine the most feasible protocol to screen patients with no clinical disease activity by ultrasound (US). METHODS: A hundred consecutive RA patients with no clinical activity according to the physician had an US scan for 38 joints...
June 16, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28625712/how-common-is-remission-in-juvenile-idiopathic-arthritis-a-systematic-review
#3
REVIEW
Stephanie J W Shoop-Worrall, Lianne Kearsley-Fleet, Wendy Thomson, Suzanne M M Verstappen, Kimme L Hyrich
OBJECTIVES: The ideal goal of treatment for juvenile idiopathic arthritis (JIA) is disease remission. However, many sets of remission criteria have been developed and no systematic review of remission in JIA exists. The current systematic review investigated (1) how remission has been defined across JIA clinical cohorts and (2) the frequency of remission overall and within disease categories. METHODS: Studies using prospective inception cohorts published after 1972 were selected if they estimated remission in cohorts of ≥50 patients...
May 20, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28622462/-determinants-of-perceived-health-non-improvement-in-early-rheumatoid-arthritis-patients-with-favorable-treatment-outcomes
#4
M A H Oude Voshaar, L M M Steunebrink, E Taal, H E Vonkeman, T R Zijlstra, M A F J van de Laar
OBJECTIVE: The aim of this study was to explore the association between achieving favorable clinical outcomes and patients' perceived change in overall health status after 12 months of treat to target (T2T) in patients with early rheumatoid arthritis and to identify determinants of subjective non-improvement. METHODS: Baseline and 12 month data of patients included in the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study with at least a moderate EULAR response after 1 year were selected for analysis...
June 16, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28622048/a-randomized-double-blind-parallel-group-phase-iii-study-of-shortening-the-dosing-interval-of-subcutaneous-tocilizumab-monotherapy-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-subcutaneous-tocilizumab-every-other-week-results-of-the-12
#5
Atsushi Ogata, Yoshiya Tanaka, Tomonori Ishii, Motohide Kaneko, Hiroko Miwa, Shino Ohsawa
OBJECTIVE: To determine the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) monotherapy every week (qw) versus every other week (q2w) in patients with rheumatoid arthritis who had an inadequate response to TCZ-SC q2w. METHODS: Adult patients in Japan with inadequate response to TCZ-SC q2w were randomized to either TCZ-SC 162 mg qw monotherapy or TCZ-SC 162 mg q2w monotherapy for 12 weeks (double-blind). The primary endpoint was the change from baseline in adjusted Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) at week 12...
June 16, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28612748/novel-treatment-strategies-in-rheumatoid-arthritis
#6
REVIEW
Gerd R Burmester, Janet E Pope
New treatment strategies have substantially changed the course of rheumatoid arthritis. Many patients can achieve remission if the disease is recognised early and is treated promptly and continuously; however, some individuals do not respond adequately to treatment. Rapid diagnosis and a treat-to-target approach with tight monitoring and control, can increase the likelihood of remission in patients with rheumatoid arthritis. In this Series paper, we describe new insights into the management of rheumatoid arthritis with targeted therapy approaches using classic and novel medications, and outline the potential effects of precision medicine in this challenging disease...
June 10, 2017: Lancet
https://www.readbyqxmd.com/read/28608433/performances-of-clinical-disease-activity-index-cdai-and%C3%A2-simplified-disease-activity-index-sdai-appear-to-be-better-than-the-gold-standard-disease-assessment-score-das-28-crp-to-assess-rheumatoid-arthritis-patients
#7
Pooja Dhaon, Siddharth K Das, Ragini Srivastava, Urmila Dhakad
BACKGROUND/PURPOSE: To compare the performance of Disease Assessment Score of 28 joints - C-reactive protein (DAS-28-CRP), Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) composite measures to assess status of patients with rheumatoid arthritis (RA) on methotrexate, versus DAS-28 CRP as the gold standard. METHODS: One hundred and thirty-five patients with RA as per the 2010 American College of Rheumatology/European League Against Rheumatism criteria were included in the prospective study...
June 12, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28608166/abatacept-a-review-in-rheumatoid-arthritis
#8
Hannah A Blair, Emma D Deeks
The biological DMARD (bDMARD) abatacept (Orencia(®)), a recombinant fusion protein, selectively modulates a co-stimulatory signal necessary for T-cell activation. In the EU, abatacept is approved for use in patients with highly active and progressive rheumatoid arthritis (RA) not previously treated with methotrexate. Abatacept is also approved for the treatment of moderate to severe active RA in patients with an inadequate response to previous therapy with at least one conventional DMARD (cDMARD), including methotrexate or a TNF inhibitor...
June 12, 2017: Drugs
https://www.readbyqxmd.com/read/28606966/obesity-and-rates-of-clinical-remission-and-low-mri-inflammation-in-rheumatoid-arthritis
#9
Michael D George, Mikkel Østergaard, Philip G Conaghan, Paul Emery, Daniel G Baker, Joshua F Baker
OBJECTIVES: Obesity has been proposed as a risk factor for refractory rheumatoid arthritis (RA). We evaluated the impact of obesity on achieving clinical and imaging definitions of low disease activity. METHODS: This study evaluated 470 patients with RA from GO-BEFORE and GO-FORWARD randomised clinical trials. Included patients had blinded clinical disease activity measures and MRI at baseline, 24 and 52 weeks. Synovitis, osteitis and total inflammation scores were determined using the RA MRI scoring system...
June 12, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28606965/low-disease-activity-das28%C3%A2-3-2-reduces-the-risk-of-first-cardiovascular-event-in-rheumatoid-arthritis-a-time-dependent-cox-regression-analysis-in-a-large-cohort-study
#10
Elke Ea Arts, Jaap Fransen, Alfons A Den Broeder, Piet L C M van Riel, Calin D Popa
OBJECTIVE: Systemic inflammation appears to contribute to the excess risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The objective of this study was to investigate the effect of different levels of disease activity over time, particularly low disease activity and remission, on CVD risk in patients with RA. METHODS: Data from the Nijmegen early RA inception cohort were used. The primary outcome was first CVD events within the first 10 years of follow-up...
June 12, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28597983/celecoxib-for-rheumatoid-arthritis
#11
REVIEW
Mahir Fidahic, Antonia Jelicic Kadic, Mislav Radic, Livia Puljak
BACKGROUND: Rheumatoid arthritis is a systemic auto-immune disorder that causes widespread and persistent inflammation of the synovial lining of joints and tendon sheaths. Presently, there is no cure for rheumatoid arthritis and treatment focuses on managing symptoms such as pain, stiffness and mobility, with the aim of achieving stable remission and improving mobility. Celecoxib is a selective non-steroidal anti-inflammatory drug (NSAID) used for treatment of people with rheumatoid arthritis...
June 9, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28597307/optimization-of-biological-therapy-in-rheumatoid-arthritis-patients-outcomes-from-the-create-registry-after-2-years-of-follow-up
#12
Manuel J Cárdenas, Soraya de la Fuente, María C Castro-Villegas, Montserrat Romero-Gómez, Desiré Ruiz-Vílchez, Jerusalem Calvo-Gutiérrez, Alejandro Escudero-Contreras, José R Del Prado, Eduardo Collantes-Estévez, Pilar Font
The current strategy for managing rheumatoid arthritis (RA) focuses on achieving clinical remission. Once remission is achieved and sustained over time, the most efficient strategy is dose optimization. This work describes the results of dose optimization after 2 years of follow-up in patients with RA treated with biological therapy and identifies predictive variables of response. Cohort: patients from the CREATE registry who, as of 1 November 2013, had been in clinical remission (DAS28 ≤2.6) for at least 6 months...
June 9, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28597306/maintenance-of-remission-with-combination-etanercept-dmard-therapy-versus-dmards-alone-in-active-rheumatoid-arthritis-results-of-an-international-treat-to-target-study-conducted-in-regions-with-limited-biologic-access
#13
Karel Pavelka, Nurullah Akkoç, Mustafa Al-Maini, Cristiano A F Zerbini, Dmitry E Karateev, Evgeny L Nasonov, Mahboob U Rahman, Ronald Pedersen, Andrew Dinh, Qi Shen, Radu Vasilescu, Sameer Kotak, Ehab Mahgoub, Bonnie Vlahos
In this transglobal, randomized, double-blind, placebo-controlled, treat-to-target study, the maintenance of efficacy was compared between biologic-and biologic-free-disease-modifying antirheumatic drug (DMARD) combination regimens after low disease activity (LDA) was achieved with biologic DMARD induction therapy. Patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy received open-label etanercept 50 mg subcutaneously once weekly plus methotrexate with or without other conventional synthetic (cs) DMARDs for 24 weeks...
June 9, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28592626/longitudinal-ip-10-serum-levels-are-associated-with-the-course-of-disease-activity-and-remission-in-rheumatoid-arthritis
#14
Anouk van Hooij, Debbie M Boeters, Elisa M Tjon Kon Fat, Susan J F van den Eeden, Paul L A M Corstjens, Annette H M van der Helm-van Mil, Annemieke Geluk
Although Rheumatoid arthritis (RA) is a chronic, persistent autoimmune disease 10-15% of the RA patients achieve sustained disease modifying anti-rheumatic drugs (DMARD)-free remission over time. Biological mechanisms underlying the resolution of persistent inflammation in RA are yet unidentified and prognostic markers are lacking.It is well established that increased serum levels of IFN-γ-induced protein 10 (IP-10) are associated with (acute) increased inflammatory responses (e.g. in leprosy). In order to assess the potential of IP-10 as a diagnostic tool for inflammatory episodes in RA, we performed a retrospective study and assessed IP-10 levels in longitudinally banked serum samples of patients upon first diagnosis of RA...
June 7, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28592052/-the-457th-case-polyarthralgia-back-pain-and-subcutaneous-masses
#15
M Li, D Wu, W J Zheng, M T Li, X F Zeng
A 54-year-old man was admitted to the Department of Rheumatology in Peking Union Medical College Hospital due to polyarthritis, back pain and multiple subcutaneous masses. He had symmetrical polyarthritis at onset, which was diagnosed as rheumatoid arthritis. His follow-up and treatment were irregular. Back pain and multiple subcutaneous masses developed 2 year ago. Erythrocyte sedimentation rate and C-reactive protein were elevated. Rheumatoid factor and Anti-cyclic citrullinated peptide antibody were positive...
June 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/28585869/postmarketing-surveillance-evaluating-the-safety-and-effectiveness-of-golimumab-in-japanese-patients-with-rheumatoid-arthritis
#16
Masayoshi Kanbori, Hiroshi Suzuka, Tsutomu Yajima, Emika Kishino, Ryuji Morishige, Shigeki Momohara, Atsushi Kawakami, Miyo Ota
OBJECTIVES: The purpose of this study was to evaluate the real-world safety and effectiveness of golimumab (GLM) in Japanese patients with rheumatoid arthritis. METHODS: A postmarketing surveillance of 5154 patients was conducted with a follow-up duration of at least 24 weeks. Patients were divided into four groups based on the initial treatment: 50 mg or 100 mg of GLM with concomitant use of methotrexate (MTX) and 50 mg or 100 mg of GLM monotherapy. Patient characteristics at baseline, safety and effectiveness were assessed for each group...
June 6, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28571245/rituximab-a-magic-bullet-for-pemphigus
#17
V Anandan, W Afthab Jameela, R Sowmiya, M Mani Surya Kumar, P Lavanya
INTRODUCTION: Pemphigus, an autoimmune disease, was fatal before the era of corticosteroids. With the advent of steroids, mortality decreased but morbidity was present due to the side effects of high dose steroids. Newer drugs targeted at the molecular level are said to have fewer side effects and improved effectiveness. AIM: The aim of our study was to assess the effectiveness of one such drug, Rituximab, a biological, in treating pemphigus vulgaris and to identify common adverse events...
April 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28569219/hdl-cholesterol-efflux-capacity-in-rheumatoid-arthritis-patients-contributing-factors-and-relationship-with-subclinical-atherosclerosis
#18
Beatriz Tejera-Segura, María Macía-Díaz, José David Machado, Antonia de Vera-González, Jose A García-Dopico, José M Olmos, José L Hernández, Federico Díaz-González, Miguel A González-Gay, Iván Ferraz-Amaro
BACKGROUND: Lipid profiles appear to be altered in rheumatoid arthritis (RA) patients because of disease activity and inflammation. Cholesterol efflux capacity (CEC), which is the ability of high-density lipoprotein cholesterol to accept cholesterol from macrophages, has been linked not only to cardiovascular events in the general population but also to being impaired in patients with RA. The aim of this study was to establish whether CEC is related to subclinical carotid atherosclerosis in patients with RA...
May 31, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28569211/exosomal-amyloid-a-and-lymphatic-vessel-endothelial-hyaluronic-acid-receptor-1-proteins-are-associated-with-disease-activity-in-rheumatoid-arthritis
#19
Jihyung Yoo, Sang Kwang Lee, Mikyung Lim, Donghyuk Sheen, Eun-Hye Choi, Soon Ae Kim
BACKGROUND: Exosomes are thought to play an important role in exchanging information between cells. The proteins and lipids in exosomes play roles in mediating inflammatory and autoimmune diseases. The aim of this study was to identify exosomal candidate proteins that are related to other inflammatory parameters in rheumatoid arthritis (RA). METHODS: The study population consisted of 60 patients with RA: 30 in the clinical remission (CR) group with a Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) ≤2...
May 31, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28560470/cost-per-response-for-abatacept-versus-adalimumab-in-rheumatoid-arthritis-by-acpa-subgroups-in-germany-italy-spain-us-and-canada
#20
Laure Weijers, Christoph Baerwald, Francesco S Mennini, José M Rodríguez-Heredia, Martin J Bergman, Denis Choquette, Kirsten H Herrmann, Giulia Attinà, Carmela Nappi, Silvia Jimenez Merino, Chad Patel, Mondher Mtibaa, Jason Foo
Rheumatoid arthritis (RA) is a chronic inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden. The Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate (AMPLE) trial was a head-to-head, randomized study comparing abatacept in serum anti-citrullinated protein antibody (ACPA)-positive patients, with increasing efficacy across ACPA quartile levels. The aim of this study was to evaluate the cost per response accrued using abatacept versus adalimumab in ACPA-positive and ACPA-negative patients with RA from the health care perspective in Germany, Italy, Spain, the US and Canada...
May 30, 2017: Rheumatology International
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"